Results 71 to 80 of about 7,450 (200)

Das Parkinson‐Medikament Tolcapon und dessen Derivative sind Potente Glykomimetische Inhibitoren des Pseudomonas aeruginosa Lektins LecA

Angewandte Chemie, Volume 137, Issue 50, December 8, 2025.
Wir stellen Tolcapon und dessen Derivate als eine neue Klasse potenter Glykomimetika zur Lektininhibition vor. Über 3.200 Verbindungen der Roche‐Substanzbibliothek wurden experimentell gescreent und eine Auswahl biophysikalisch untersucht. Unsere Ergebnisse zeigen das Potenzial zur Entwicklung potenter nicht‐kohlenhydratbasierter glykomimetischer ...
Steffen Leusmann, Eike Siebs, Sakonwan Kuhaudomlarp, Annabelle Varrot, Anne Imberty, Bernd Kuhn, Christian Lerner, Uwe Grether, Alexander Titz   +8 more
wiley   +1 more source

Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi. [PDF]

, 2013
Newly synthesized proteins and lipids are transported across the Golgi complex via different mechanisms whose respective roles are not completely clear. We previously identified a non-vesicular intra-Golgi transport pathway for glucosylceramide (GlcCer)--
Burke JE, Capuani F, Chuang CC, D'Angelo G, D'Auria S, Daniele T, DE MATTEIS, Maria Antonietta, Di Tullio G, Harada A, Johannes L, Mattjus P, MONTI, MARIA, Ohvo Rekilä H, Platt FM, Polishchuk E, PUCCI, PIETRO, Santoro M, Sato T, Uemura T, Varriale A, Williams RL   +20 more
core   +1 more source

The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA

Angewandte Chemie International Edition, Volume 64, Issue 50, December 8, 2025.
We present Tolcapone and derivatives as a new class of potent glycomimetics for lectin inhibition. Over 3200 Roche in‐house compounds were screened experimentally and a subset was biophysically evaluated. Our findings show the potential to develop potent non‐carbohydrate glycomimetic lectin inhibitors, opening a path toward innovative anti‐infective ...
Steffen Leusmann, Eike Siebs, Sakonwan Kuhaudomlarp, Annabelle Varrot, Anne Imberty, Bernd Kuhn, Christian Lerner, Uwe Grether, Alexander Titz   +8 more
wiley   +1 more source

Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease

Orphanet Journal of Rare Diseases, 2023
Background Fabry disease (FD) is a progressive multisystemic disease characterized by a lysosomal enzyme deficiency. A lack of α-galactosidase A (α-Gal A) activity results in the progressive systemic accumulation of its substrates, including ...
Mulan Deng, Hongyu Zhou, Shaomei He, Haoheng Qiu, Yanping Wang, April Yuanyi Zhao, Yunping Mu, Fanghong Li, Allan Zijian Zhao   +8 more
doaj   +1 more source

Fabry disease: will markers of early disease enable early treatment and better outcomes? [PDF]

, 2016
PURPOSE OF REVIEW: This review explores the clinical and pathological features of Fabry disease. New modalities of imaging, biomarkers and long-term treatment effects are discussed. RECENT FINDINGS: Fabry disease is clinically heterogeneous, and in women
Hughes, DA
core  

Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. [PDF]

, 2015
BACKGROUND: We present the case of a white 35-year-old male with a diagnosis of Fabry disease and negative family history. CASE PRESENTATION: At the age of 31, he underwent a renal biopsy with a diagnosis of hypertension-induced nephroangiosclerosis.
Daniele, Aurora, Di Domenico, Carmela, Nigro, Ersilia, Pisani, Antonio, Riccio, Eleonora, Salvatore, Francesco   +5 more
core   +3 more sources

Connecting the Dots: Bridging Microsamples and Conventional Blood Matrices in Metabolic Biomarker Analysis

Analytical Science Advances, Volume 6, Issue 2, December 2025.
ABSTRACT Bridging the gap between microsampling techniques and standard blood matrices presents a groundbreaking opportunity in metabolic biomarker analysis, offering minimally invasive, patient‐centric alternatives to traditional venipuncture. This review presents the current knowledge obtained from the comparison of biomarkers analysis in liquid ...
Marlene Thaitumu, Vasiliki Gkanali, Georgios Theodoridis, Helen Gika   +3 more
wiley   +1 more source

NEUROLOGICAL MANIFESTATIONS OF FABRY DISEASE IN CHILDREN AND ADOLESCENTS

Русский журнал детской неврологии, 2017
Fabry disease (Anderson–Fabry disease) is an X-linked recessive lysosomal storage disorder resulting from deficient activity of lysosomal hydrolase, alpha-galactosidase A, which leads to progressive accumulation of globotriaosylceramide (Gb3) in various ...
A. S. Kotov, K. V. Firsov
doaj   +1 more source

Diagnostic oriented discrimination of different Shiga toxins via PCA‐assisted SERS‐based plasmonic metasurface

Nanophotonics, Volume 14, Issue 23, Page 4005-4018, 02 November 2025.
Abstract Plasmonic biosensors are powerful platforms for detecting various types of analytes. Specifically, surface‐enhanced Raman spectroscopy (SERS) can enable label‐free and selective detection. Shiga toxin‐producing Escherichia coli (STEC) represents zoonotic pathogens that cause severe diseases, such as hemolytic uremic syndrome (HUS), the most ...
Massimo Rippa, Alessia Milano, Valentina Marchesano, Domenico Sagnelli, Bryan Guilcapi, Amalia D'Avino, Giovanna Palermo, Giuseppe Strangi, Luciano Consagra, Maurizio Brigotti, Stefano Morabito, Joseph Zyss, Lucia Petti   +12 more
wiley   +1 more source

Shiga Toxins: An Update on Host Factors and Biomedical Applications

Toxins, 2021
Shiga toxins (Stxs) are classic bacterial toxins and major virulence factors of toxigenic Shigella dysenteriae and enterohemorrhagic Escherichia coli (EHEC).
Yang Liu, Songhai Tian, Hatim Thaker, Min Dong   +3 more
doaj   +1 more source